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PolymorphismAbstract In this work we studied association of common variants in transcription factor 7-like 2
(TCF7L2) and cyclin-dependent kinase 5 regulatory subunit-associated protein 1-like 1 (CDKAL1)
genes with type 2 diabetes mellitus (T2DM) in Egyptians.
Subjects and methods: This is a case–control study; 180 T2DM patients and 210 control subjects
were genotyped for TCF7L2 rs7903146 and rs12255372 and CDKAL1 rs7756992 single nucleotide
polymorphisms (SNPs) by TaqMan method on real time polymerase chain reaction system (real
time-PCR).
Results: TCF7L2 rs12255372 and rs7903146 associated with T2DM (p= 0.0001 and 0.003;
respectively). The rs12255372 variant T allele associated with 2-fold increased risk for T2DM
and TT genotype carriers were at 3.58-folds higher risk to develop T2DM than wild genotype
(GG) carriers. Meanwhile, rs7903146 variant T allele associated with 1.6-fold increased risk for
T2DM and TT genotype carriers were at 2.3-folds higher risk than wild genotype (CC) carriers.
Both TCF7L2 SNPs significantly associated with T2DM under additive and dominant models
and after adjustment for other covariates. On the other hand, CDKAL1 rs7756992 showed no sig-
nificant association with T2DM under any genetic model. Both TCF7L2 SNPs were in strong LD
(P= 0.02; D0 = 0.85). Taking common TCF7L2 rs12255372/rs7903146 GC haplotype as reference,
multivariate analysis confirmed the association of rs12255372 T allele-containing haplotypes (TC
and TT) with T2DM. Haplotype TC associated with 6.32 times-higher risk for T2DM (95%
CI = 0.55–76.17, Pc = 0.04) followed by haplotype TT which associated with 3.88 times-higher
risk for the disease (95%CI = 1.09–13.76, Pc = 0.03).
Conclusion: TCF7L2 rs12255372 and rs7903146 common variants associate with T2DM risk in
Egyptians.
 2016 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research &
Technology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Type 2 diabetes mellitus (T2DM) is a metabolic disorder
caused by decreased insulin sensitivity and impaired insulin
secretion due to pancreatic beta cell defect [1]. In addition to
248 D. El-Lebedy, I. Ashmawyenvironmental and lifestyle risk factors, genetic factors play an
important role in disease pathogenesis [2]. So, identification of
genetic architecture of T2DM is of great interest for risk pre-
diction and preventive interventions.
T2DM represents a global major healthcare burden [3].
According to the International Diabetes Federation (IDF),
Egypt is in the world 8th place in terms of diabetes incidence,
affecting up to 9.3% of population, and due to a rapidly
increasing and aging population, Egypt will have the highest
number of people with diabetes in the region by 2025 [4].
According to genome-wide association studies (GWAS)
and meta-analysis; more than 50 gene variants were identified
to be associated with T2DM. Two common variants in tran-
scription factor 7-like 2 (TCF7L2) gene on chromosome
10q25.3 have brought the most attention and were reported
as the strongest genetic risk factor for T2DM [5]; a C-to-T sub-
stitution in intron 3 (IVS3C > T, rs7903146) [6–8] and a G-to-
T substitution in intron 4 (IVS4G> T, rs12255372) [6,9]. The
exact mechanism through which TCF7L2 variants affect the
risk for T2DM is still unclear. It has been postulated that
TCF7L2 gene variants may indirectly alter glucagon-like pep-
tide 1 (GLP-1) levels, an insulinotropic hormone which plays a
critical role in blood glucose homeostasis [10].
One of the loci most consistently associated with T2DM
risk is the intronic variant within the cyclin-dependent kinase
5 regulatory subunit-associated protein 1-like 1 (CDKAL1)
gene; A-to-G substitution in intron 5 (IVS5A >G,
rs7756992) [11].
CDKAL1 gene, located on chromosome 6p22.3, encodes a
65-kD protein (CDKAL1) which is implicated in beta cell dys-
function and T2DM susceptibility [12]. CDKAL1 might regu-
late insulin secretion induced by cyclin-dependent kinase 5
(CDK5) by binding to the CDK5 activator p35 [13–15]. It was
postulated that down regulation of CDKAL1 expression might
increase the activity of CDK5 [16]. However, the exact patho-
genesis of how CDKAL-1 modulates insulin release in pancre-
atic beta cells and the susceptibility to T2DM by interactions
between these proteins still need more investigations [17].
Association studies of these genetic variants with T2DM
risk gave inconsistent results in populations from different eth-
nic origins, which have been attributed to ethnic variations,
linkage disequilibrium pattern, as well as other non-genetic
factors [18]. This is the first study to investigate the association
of TCF7L2 rs7903146 and rs12255372 and CDKAL1
rs7756992 variants with T2DM risk in Egyptians.
2. Subjects and methods
2.1. Subjects
A total of 390 subjects, including 180 unrelated T2DM
patients and 210 healthy controls, were enrolled in the current
study. T2DM patients were recruited from the outpatient clinic
of the National Diabetes & Endocrinology Institute. Diagnosis
of diabetes based on the diagnostic criteria of the American
Diabetes Association 2014 [19], i.e. fasting plasma glucose
(FPG)P 126 mg/dL or 2 h plasma glucose (PPG)P 200 mg/
dl or random plasma glucose (RBG)P 200 mg/dl. Exclusion
criteria were type 1 diabetes (T1DM), maturity onset diabetes
of the young (MODY), or type 2 diabetes diagnosed before the
age of 30 years.Control subjects had normal glucose tolerance confirmed
by fasting plasma glucose (FPG) < 126 mg/dl or 2 h plasma
glucose (PPG) < 200 mg/dl or random plasma glucose (ran-
dom blood sugar) (RBG) < 200 mg/dl, and no first-degree
family history of diabetes. Informed consent was obtained
from all subjects and the study protocol was approved by
the Ethics Committee of the National Research Centre.
Clinical examination was applied including measurement of
systolic blood pressure (SBP) and diastolic blood pressure
(DBP). Anthropometric measurements (weight and height)
were collected and used for BMI calculation according to the
standard formula BMI = weight (kg)/[height (m)]2.
2.2. Biochemical analysis
Blood samples for biochemical screening tests were obtained
from all subjects after a 12 h overnight fast. FPG, TC (total
cholesterol), TG (triglycerides), HDL-C (high density lipopro-
tein cholesterol), LDL-C (low density lipoprotein cholesterol)
and HbA1c (glycated Hb) were assayed on Cobas c311 auto
analyzer (Roche Diagnostics, Germany).
2.3. Genotyping analysis
Genomic DNA was extracted from peripheral blood using
QIAamp DNA extraction kit (Qiagen Hilden, Germany)
according to the manufacturer’s protocol. TCF7L2 gene SNP
rs7903146 (assay ID: C_29347861_10) and SNP rs12255372
(assay ID: C_291484_20) and CDKAL1 SNP rs7756992 (assay
ID: C_2504058_20) were genotyped by TaqMan allelic dis-
crimination method on ABI 7500 real-time PCR system
(Applied Biosystems, Foster City, CA). All primers and probes
were designed by Applied Biosystems (Foster City, CA). For
genotyping quality control, 10% of samples were randomly
selected and measured in duplicates and the concordance rate
was 100%.
2.4. Statistical analysis
Data were analyzed using SPSS version 16.0 for Windows
(Chicago, IL, USA). Data were expressed as mean ± SD for
continuous variables and as percentages of total for categorical
variables. Intergroup significance was assessed by Student’s t-
test for continuous variables and v2 test for categorical vari-
ables. The Hardy–Weinberg equilibrium was estimated by v2
test. Chi-square was used to test the difference in alleles and
genotypes frequency between groups. The Bonferroni correc-
tion method was applied for multiple testing. Associations of
genotypes and alleles with T2DM were evaluated by logistic
regression after adjustment for other covariates. Odds ratios
(ORs), 95% confidential intervals (CIs) and P values were cal-
culated. P value less than 0.05 was considered significant.
3. Results
3.1. General characteristics of the study subjects
The study included 390 subjects classified into 180 patients
with T2DM and 210 control subjects. Their age ranged from
40 to 60 (years). Clinical and biochemical data are shown in
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were identified in gender, BMI, SBP, DBP and lipid profile
parameters; accordingly, those were the potential covariates
that were controlled for in the subsequent analysis.
3.2. Association studies
Significantly higher minor allele frequency (MAF) of TCF7L2
rs12255372 and rs7903146 were identified in T2DM patients
(p= 0.0001 and 0.003, respectively). While MAF of CDKAL1
rs7756992 showed no significant difference between patients
with T2DM and control subjects (p= 0.2) (Table 2). Both
TCF7L2 SNPs significantly associated with T2DM under
additive and dominant models, but not the recessive model.
In contrast, CDKAL1 rs7756992 did not show association with
T2DM under any genetic model. Table 3 summarizes the asso-
ciation studies of these genetic variants with T2DM under dif-
ferent models.
3.3. Haplotype analysis
Both TCF7L2 SNPs were in strong LD (P= 0.02; D0 = 0.85).
Taking the common TCF7L2 rs12255372/rs7903146 GC hap-
lotype as reference (OR = 1.0), multivariate analysis con-
firmed the association of rs12255372T allele-containing
haplotypes (TT, TC) with T2DM. TT haplotype carriers were
3.88 times-at risk for T2DM (OR= 3.88, 95%CI = 1.09–
13.76, Pc = 0.03), while TC haplotype carriers were 6.32
times-at risk for T2DM (OR= 6.3295%CI = 0.55–76.17,
Pc = 0.04) (Table 4).
4. Discussion
The association between TCF7L2 rs7903146 and rs12255372
and CDKAL1 rs7756992 SNPs and T2DM susceptibility has
been widely studied in different populations [5,14,20,21].
However, studies in different ethnic groups gave inconsistentTable 1 Demographic and biochemical characteristics of the
study population.
Characteristic Controls
(n= 210)
T2DM
(n= 180)
Age (Years) 53.40 ± 5.2 55.3 ± 6.1
Gender (male/female) 112/98 115/65*
BMI (kg/m2) 24.65 ± 3. 21 27.31 ± 4.74*
Diabetes duration (Years) – 7.9 ± 4.5
SBP (mm/Hg) 118.4 ± 11.2 132.6 ± 18.5*
DBP (mm/Hg) 79.6 ± 14.9 83.7 ± 13.2*
FPG (mg/dL) 86.16 ± 13.92 152.8 ± 14.5*
HbA1c (%) 4.9 ± 0.36 6.51 ± 1.21*
Triglycerides (mg/dL) 99.56 ± 34.18 127.6 ± 28.2*
TC (mg/dL) 182.7 ± 29.09 190.1 ± 41.56*
LDL-C (mg/dL) 104.7 ± 25.85 127.22 ± 31.9*
HDL-C (mg/dL) 51.9 ± 8.7 47.9 ± 10.2*
BMI: body mass index; SBP: systolic blood pressure; DBP: dias-
tolic blood pressure; FPG: fasting plasma glucose; HbA1c: glycated
Hb; TG: triglycerides; TC: total cholesterol; LDL-C: low density
lipoprotein cholesterol; HDL-C: high density lipoprotein
cholesterol.
* Significant p.results, while some replication studies confirmed this
association, other studies failed to find significant association,
proposing an ethnic variability.
TCF7L2 gene variants have been replicated in many ethnic
groups and were associated with T2DM [5], including
Caucasians [22], Europeans [23], Indians [24], Africans [20],
and East Asians [25,26]. Among which, rs7903146 and
rs12255372 SNPs showed the strongest association with dis-
ease susceptibility [5,6,20–26]. In Arabs, association between
TCF7L2 variants and T2DM varied, while strong association
was demonstrated in Tunisians [27], Moroccans [5], Omanis
[28] and Palestinians [29], weak or no significant association
was reported in United Arab Emirati [30] or Saudi Arabians
[31].
This is the first study to examine the association of these
SNPs with T2DM in Egyptians. Our results extend the list of
populations in which TCF7L2 rs12255372 and rs7903146 are
associated with T2DM. The strongest association was with
TCF7L2 rs12255372 (p= 0.0001) followed by rs7903146
(p= 0.003). The rs12255372T allele associated with 2-fold
increased risk of T2DM and TT genotype increased the risk
by 3.58-folds when compared with GG genotype. Meanwhile,
rs7903146T allele associated with 1.6-fold increased risk while
TT genotype increased the risk of disease by 2.3-fold when
compared to CC genotype. Both SNPs were significant under
additive and dominant models, but not the recessive model
which might be attributed to the small sample size and low fre-
quency of genotypes homozygous for the variant alleles in our
sample.
In Tunisians, rs7903146T allele associated with increased
susceptibility to T2DM and TT genotype carriers were at
56% higher risk of T2DM than CC genotype carriers [27],
while in United Arab Emirati subjects, T2DM associated with
rs12255372T variant but not rs7903146T variant with no asso-
ciation with metabolic syndrome, beta cell function or insulin
resistance [30]. In Palestinians, rs7903146T variant associated
with a 3.34 times higher risk of T2DM and TT genotype asso-
ciated with an earlier onset of disease [29].
In a large meta-analysis, including data from 36 genetic
association studies with 35,843 patients with T2DM and
39,123 controls, an association between TCF7L2 gene and
T2DM has been demonstrated. In which, rs7903146 CT geno-
type associated with a 1.4-fold higher risk for T2DM and TT
genotype with a 2-fold increased risk when compared with wild
genotype. The rs12255372 GT genotype associated with
1.4-fold increased risk of T2DM and TT genotype with a
1.9-fold higher risk for T2DM when compared with wild geno-
type [32].
In our patients, we could not replicate the association of
CDKAL1 rs7756992 with T2DM. CDKAL1 rs7756992 has
been associated with T2DM and functional studies indicated
its relationship to impaired insulin secretion [33] by binding
to the CDK5 activator p35 [13].
Our results were consistent with previous studies [21,34,35].
However, in a study on Lebanese population, rs7756992 asso-
ciated with T2DM and the risk estimate conferred by the vari-
ant G allele was 1.3 [18].
A meta-analysis involved 62,567 subjects from 21 studies
demonstrated a significant association between rs7756992
and T2DM. In the subgroup analysis, significant association
was found in Caucasians and Asians, while no significant asso-
ciation was detected in Africans [36]. In another meta-analysis
Table 2 Association of TCF7L2 and CDKAL1 SNPs with T2DM.
Gene SNP Cases MAF Controls MAF P OR (95%CI)
TCF7L2 rs7903146 0.38 0.24 0.003 1.62 (1.17–2.25)
rs12255372 0.37 0.17 0.0001 2.06 (1.45–2.93)
CDKAL1 rs7756992 0.40 0.45 0.2 0.81 (0.60–1.11)
MAF: minor allele frequency (defined based on frequency in controls).
Table 3 Association of TCF7L2 and CDKAL1 gene variants with T2DM risk under different models.
SNP Genotype distributiona Additive model Dominant model Recessive model
Controls N= 210 Patients N= 180 OR (95%CI) P OR (95%CI) P OR (95%CI) P
TCF7L2
rs7903146
C/C 112 (53.3) 48 (26.6) 1.0 (Reference)
C/T 95 (45.2) 126 (70) 3.09 (2.01–4.75) <0.00001 3.14(2.04–4.81) <0.0001 2.37 (0.58–9.65) 0.22
T/T 3 (1.5) 6 (3.4) 4.6 (1.12–19.43) C/C vs. C/T + T/T C/C + C/T vs. T/T
rs12255372
G/G 139(66.2) 60 (33.3) 1.0 (Reference)
G/T 69 (32.9) 114 (63.4) 4.05 (2.65–6.2) <0.00001 3.9 (2.56–5.96) <0.0001 3.58 (0.71–17.99) 0.12
T/T 2 (0.9) 6 (3.3) 4.65 (1.12–19.14) G/G vs. G/T + T/T G/G+ G/T vs. T/T
CDKAL1
rs7756992
A/A 63 (30) 60 (33.3) 1.0 (Reference)
A/G 105 (50) 96 (53.3) 0.96 (0.61–1.5) 0.21 0.85 (0.55–1.31) 0.48 0.61 (0.35–1.06) 0.08
G/G 42 (20) 24 (13.4) 0.6 (0.32–1.1) A/A vs. A/G+ G/G A/A+ A/G vs. G/G
a Data shown as number of subjects (frequency).
Table 4 TCF7L2 rs12255372/rs7903146 haplotype distribution in patients and controls.
Haplotype Controls (%) Patients (%) Pc OR (95%CI)
G C 50 20 <0.00001 1.0 (reference)
T T 38.5 50 0.03 3.88 (1.09–13.76)
T C 0 10 0.04 6.32 (0.55–76.17)
G T 11.5 20 0.07 4.66 (0.86–25.13)
Data were calculated by multivariate analysis.
Pc: corrected p after applying Bonferroni correction.
250 D. El-Lebedy, I. Ashmawyof 27 studies on CDKAL1 rs7756992 involving 28,383 T2DM
patients and 47,635 controls, the overall risk estimate for
T2DM conferred by rs7756992G allele was 1.2 [37]. In a study
investigating the association between T2DM risk variants and
reduced birth weight in Chinese Han individuals, among 12
genetic variants, CDKAL1 rs7756992 associated with increased
risk of impaired glucose metabolism, low birth weight and
decreased insulin secretion index later in life [17].
In conclusion, TCF7L2 rs12255372 and rs7903146 common
variants associate with T2DM susceptibility in Egyptians;
however, we could not identify such association for CDKAL1
rs7756992 variant in our patients.
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